Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.

Int J Mol Sci · 2022 · PMC9316488 · PMID 35887398

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

These results were in line with the results of the clonogenic survival assay, where the veliparib combination therapy showed the largest effect compared to veliparib monotherapy, although this effect did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.